186
Participants
Start Date
August 9, 2023
Primary Completion Date
April 1, 2028
Study Completion Date
April 30, 2028
Definity
Ultrasound contrast agent administered intravenously
Super-resolution ultrasound imaging
Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Mayo Clinic Florida, Jacksonville
Mayo Clinic Minnesota, Rochester
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Mayo Clinic
OTHER